| |
| |
|
| Insider
Information: |
Kauffman Michael |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
800,347 |
|
|
Indirect Shares
|
898,131 |
|
|
| Direct
Value |
$892,799 |
|
|
|
Indirect Value
|
$952,019 |
|
|
| Total
Shares |
1,698,478 |
|
|
| Total
Value |
$1,844,817 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
12
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
12
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-12.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -553.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
Chief Medical Officer |
2010-02-09 |
9,000 |
2009-11-16 |
0 |
Premium* |
|
|
Karyopharm Therapeutics Inc. |
KPTI |
Director |
2022-02-28 |
713,757 |
2022-02-28 |
898,131 |
Premium* |
|
|
Verastem, Inc. |
VSTM |
Director |
2018-09-28 |
8,000 |
2014-09-17 |
0 |
Premium* |
|
|
Kezar Life Sciences, Inc. |
KZR |
Director |
2022-01-03 |
63,690 |
2018-06-25 |
0 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
Director |
2023-06-01 |
5,900 |
2023-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ACET |
Adicet Bio, Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
5,900 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-28 |
4 |
S |
$10.24 |
$63,739 |
I/I |
(6,226) |
898,131 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-28 |
4 |
S |
$10.24 |
$63,739 |
D/D |
(6,226) |
713,757 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
719,983 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-17 |
4 |
S |
$12.12 |
$110,068 |
D/D |
(9,079) |
698,983 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-17 |
4 |
S |
$12.12 |
$110,177 |
I/I |
(9,088) |
904,357 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-07 |
4 |
S |
$9.86 |
$66,144 |
I/I |
(6,707) |
913,445 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-07 |
4 |
S |
$9.86 |
$66,707 |
D/D |
(6,764) |
708,062 |
0 |
% |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2022-01-03 |
4 |
AS |
$16.45 |
$82,250 |
D/D |
(5,000) |
63,690 |
0 |
% |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2022-01-03 |
4 |
OE |
$5.91 |
$29,550 |
D/D |
5,000 |
68,690 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-03-18 |
4 |
AS |
$12.39 |
$49,553 |
D/D |
(4,000) |
714,826 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
I/I |
57,200 |
920,152 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
57,200 |
718,826 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-18 |
4 |
S |
$14.83 |
$140,822 |
I/I |
(9,495) |
776,452 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-18 |
4 |
S |
$14.83 |
$140,822 |
D/D |
(9,495) |
575,126 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
21,800 |
785,947 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,800 |
584,621 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-11 |
4 |
S |
$15.52 |
$103,077 |
I/I |
(6,642) |
764,147 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-11 |
4 |
S |
$15.52 |
$102,441 |
D/D |
(6,601) |
562,821 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,300 |
569,422 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
I/I |
14,300 |
770,789 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2020-10-12 |
4 |
AS |
$14.89 |
$111,683 |
I/I |
(7,500) |
756,489 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2020-10-12 |
4 |
OE |
$0.03 |
$248 |
I/I |
7,500 |
763,989 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2020-08-17 |
4 |
AS |
$15.00 |
$22,155 |
I/I |
(1,477) |
756,489 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2020-08-17 |
4 |
OE |
$0.03 |
$49 |
I/I |
1,477 |
757,966 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
